Cannabidiol as a potential treatment for psychosis

  title={Cannabidiol as a potential treatment for psychosis},
  author={Christian D. Schubart and I. Sommer and Paolo Fusar-Poli and Lot D. de Witte and R. S. Kahn and Marco P. M. Boks},
  journal={European Neuropsychopharmacology},

Tables from this paper

Could cannabidiol be used as an alternative to antipsychotics?
  • M. Fakhoury
  • Psychology, Medicine
    Journal of psychiatric research
  • 2016
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments, and CBD may also have anti-inflammatory and neuroprotective properties.
A systematic review of the antipsychotic properties of cannabidiol in humans
Cannabidiol for psychosis: A review of 4 studies
Some recent studies that examined the effects of CBD on psychosis found that individuals who use CBD may experience fewer positive psychotic symptoms compared with placebo, raising the question of whether CBD may have a role in the treatment of schizophrenia and other psychotic disorders.
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia, and preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings.
The Association Between Cannabinoids and Psychosis
The high rates and earlier onset of cannabis use, the legalization of “medical” marijuana (cannabis) and recreational cannabis use in some states, the increasing availability and use of edible cannabinoid products and highly potent synthetic cannabinoids, and the increasing potency of cannabis warrant the need to understand the relationship between cannabinoids and psychosis.
Narrative Review of Cannabidiol as an Antipsychotic and Recommendations for Legal Regulations
Early evidence shows that CBD may be a novel and viable treatment for psychosis, which may have an effect on the regulation of CBD and THC percentages in regards to the prevention of early onset schizophrenia.
Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial
The results of this trial can potentially contribute with a new treatment paradigm for patients suffering from dual diagnosis by evaluating the efficacy of cannabidiol versus a first-choice second-generation antipsychotic (risperidone).


Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
Hair samples were analysed to examine levels of Δ9-THC and CBD in 140 individuals and three clear groups emerged: ’THC only’, ‘THC+CBD’ and those with no cannabinoid in hair, which provides evidence of the divergent properties of cannabinoids.
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded to
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia.
Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review.
Cannabidiol (CBD) was shown to prevent THC associated hippocampal volume loss in a small pilot study and is supported by several animal experiments supporting neuroprotective properties of CBD mainly via anti-oxidative effects, CB2 receptors or adenosine receptors.
Causal association between cannabis and psychosis: examination of the evidence
Cases of psychotic disorder could be prevented by discouraging cannabis use among vulnerable youths and research is needed to understand the mechanisms by which cannabis causes psychosis.
High-potency cannabis and the risk of psychosis
The finding that people with a first episode of psychosis had smoked higher-potency cannabis, for longer and with greater frequency, than a healthy control group is consistent with the hypothesis that Δ9-THC is the active ingredient increasing risk of psychosis.
Role of cannabis and endocannabinoids in the genesis of schizophrenia
Cannabis abuse is a risk factor for psychosis in genetically predisposed people, it can affect neurodevelopment during adolescence leading to schizophrenia, and a dysregulation of the endocannabinoid system can participate in schizophrenia.